JNJ-4528 Continues to Show Durable Responses in Relapsed/Refractory Multiple Myeloma

The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Source: CancerNetwork - June 7, 2020 Category: Cancer & Oncology Authors: Tony Berberabe, MPH Source Type: news